Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (497)	1/31/1999 12:27:00 PM
From: John Metcalf	Respond to of 1073

smh, there's a difference between a "frenzied" market and a healthy market. When the hype rises to the level of a general "cure for cancer", it's time to get out of the stock. Quality companies have successful products that ameliorate _some_ cancers in _some_ people, and they have been great investments, like IDPH which developed Rituxan with GNE. There are promising products, which may be solid investments, in the hands of responsible management. Unfortunately, investors succumb frequently to stories that some company worth $<100mm, which can't get funding, has wrapped up the whole enchilada. Not likely, though they may have something of value. Rick keeps making this point: managers and owners that have over-hyped a series of goners are big red flags.